How the Evidence Separates COPD From Asthma

The short answer: there is no single test that cleanly tells chronic obstructive pulmonary disease from asthma. Both are diseases of narrowed airways, and a clinician sorts them by reading three things at once, your story, what spirometry shows before and after an inhaled bronchodilator, and whether the narrowing is fixed or comes and goes. Each clue points a direction. None of them, alone, closes the case.

Key points#

• COPD and asthma are defined by nearly opposite properties: COPD by airflow limitation that persists, asthma by airflow limitation that varies.
• GOLD 2025 anchors COPD to a post-bronchodilator FEV1/FVC ratio below 0.70 that does not normalize; GINA 2024 anchors asthma to documented variable expiratory airflow limitation.
• The patient's history (age of onset, smoking or biomass smoke, whether symptoms fluctuate or steadily worsen) does much of the sorting before any tracing is printed.
• A large rise in FEV1 after a bronchodilator was once treated as an asthma marker; it turns out many people with COPD respond too, so the test discriminates poorly.
• When features of both conditions coexist, guidelines describe asthma-COPD overlap rather than force a single label, and they keep an inhaled corticosteroid in the regimen for safety.

Two definitions built on opposite properties#

Start with what each guideline is actually measuring. The GOLD 2025 report defines COPD by narrowing that stays. Its spirometric criterion is a post-bronchodilator FEV1/FVC below 0.70, measured after an inhaled bronchodilator so the number reflects fixed narrowing rather than a passing spasm. That reading is meant to sit alongside a matching clinical picture: chronic breathlessness, cough, or sputum in someone with a relevant risk factor such as tobacco, occupational dust, or biomass smoke.

The GINA 2024 report defines asthma by the opposite trait, variability. It asks for a history of respiratory symptoms (wheeze, breathlessness, chest tightness, cough) that change over time and in intensity, together with confirmed variable expiratory airflow limitation. The load-bearing word is variable. Asthma is narrowing that comes and goes, and that single property shapes both how it is found and how it slips past a snapshot test.

Why the story usually leads#

Before a spirometer is touched, the history has often already tilted the odds. Asthma tends to declare itself in childhood or early adult life, frequently alongside eczema, hay fever, or a family history of allergy. Its symptoms flare with identifiable triggers, allergens, exercise, cold air, or a viral cold, and they are often worse overnight or first thing in the morning.

COPD usually appears later, after roughly age 40, in a person who has accumulated a heavy smoking history in pack-years or years of biomass smoke, and its breathlessness is steadier and slowly progressive rather than episodic. These are tendencies, not verdicts. A lifelong smoker can genuinely have asthma, and a person who never smoked can develop fixed narrowing. The history narrows the field; it does not fence it off.

What spirometry can settle, and what it cannot#

Spirometry earns its place by answering one focused question: after a bronchodilator, does the obstruction remain? If the FEV1/FVC ratio stays below 0.70 despite treatment, the narrowing is fixed, which is the signature of COPD. If airflow returns toward normal, the picture leans toward asthma.

Even here the tool has edges it cannot see past. The fixed 0.70 cutoff overcalls obstruction in some healthy older adults, whose ratio naturally drifts down with age, and it can miss early disease in younger people. For that reason the GOLD Science Committee, writing in the European Respiratory Journal in 2025, advised using pre-bronchodilator spirometry to help exclude COPD and post-bronchodilator spirometry to confirm it, repeating the test on a separate day when the ratio lands in the borderline band between 0.60 and 0.80, and reading it against a lower limit of normal where that helps. Spirometry tells you whether the narrowing is fixed or variable on the day it is measured. It does not, by itself, name the disease that produced it.

The reversibility clue that stopped being decisive#

For years a big jump in FEV1 after a bronchodilator was treated as proof of asthma. GINA 2024 still counts a rise of at least 12 percent and at least 200 mL from baseline in adults as evidence of variable airflow limitation, with more confidence when it reaches 15 percent and 400 mL. The trouble is that this response cuts both ways.

The GOLD Science Committee noted that acute bronchodilator responsiveness was historically promoted to separate the two conditions, yet many people with COPD post strong flow or volume responses, which strips the test of discriminating power. The mirror problem is that asthma is variable by nature, so you can walk in on a calm day and produce a normal, non-reversible tracing that hides the disease entirely. GINA therefore recommends repeating spirometry while the patient is symptomatic and after holding bronchodilators, rather than trusting a single negative reading. One reversibility number, standing alone, sorts almost no one.

When both conditions share one chest#

Some patients carry features of each at the same time: a smoking history and fixed narrowing sitting next to marked reversibility, allergy, or blood eosinophilia. GINA and GOLD have long called this asthma-COPD overlap, and GINA is careful to say it is not a distinct disease with its own biology. It is a practical label for people whose features straddle the two definitions.

That is the deeper reason no single test resolves the question. Every distinguishing variable, age of onset, smoking history, reversibility, symptom pattern, sits on a continuum, and you can land in the middle of all of them at once. The line the definitions draw is sharp; the biology underneath it is not.

Why the label still steers treatment#

If the categories blur, why insist on them? Because the classification changes what is safe to prescribe. GINA points to evidence that patients with features of both asthma and COPD face a higher risk of hospitalization or death when treated with long-acting bronchodilators alone, so an inhaled corticosteroid should stay in their regimen. Mislabeling such a patient is not a tidy academic slip; it points treatment the wrong way. That single fact is why the guidelines keep asking for the full combination, history, bronchodilator response, and spirometry, instead of any one shortcut.